Aptevo Therap

Q2 FY2026 EarningsQ2 FY26 reported in-line revenue of $0.0M, consistent with its status as a clinical-stage biotech. The company delivered a significant beat on GAAP EPS, reporting -$3.75 compared to the consensus mean of -$6.02, driven by disciplined expense management and non-dilutive funding. Strategic progress was headlined by strong Phase 1b AML data for mipletamig and a new 50/50 radiopharmaceutical collaboration with Niowave, though the cash position remains tight at $9.8M.